<DOC>
	<DOCNO>NCT02500706</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . The purpose confirm efficacy term glycaemic control treatment mealtime faster-acting insulin aspart combination insulin degludec adult Type 1 Diabetes Mellitus .</brief_summary>
	<brief_title>Efficacy Safety Faster-acting Insulin Aspart Compared NovoRapidÂ® Both Combination With Insulin Degludec Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Male female , age great equal 18 year ( Japan Taiwan : age great equal 20 year ) time sign informed consent Type 1 Diabetes Mellitus ( base clinical judgement and/or support laboratory analysis per local guideline ) 12 month prior screen Currently treat basalbolus insulin regimen least 12 month prior screen ( Visit 1 ) Currently treat basal insulin analogue least 4 month prior screen ( Visit 1 ) HbA1c 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) assess central laboratory Body Mass Index less equal 35.0 kg/m^2 Within past 180 day follow : myocardial infarction , stroke hospitalization unstable angina and/or transient ischemic attack Subjects presently classify New York Heart Association ( NYHA ) Class IV Currently plan coronary , carotid peripheral artery revascularisation Diabetic ketoacidosis require hospitalisation within last 180 day prior screen ( Visit 1 ) Treatment medication indication diabetes obesity state inclusion criterion period three month screen ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>